Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 16.29 -0.79% -0.13
HALO closed down 0.79 percent on Thursday, September 19, 2019, on approximately normal volume. It ran into resistance at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical HALO trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Fell Below 50 DMA Bearish -0.79%
20 DMA Support Bullish -0.79%
MACD Bullish Centerline Cross Bullish -0.79%
Bollinger Band Squeeze Range Contraction -0.79%
NR7 Range Contraction -0.79%
Inside Day Range Contraction -0.79%
20 DMA Support Bullish -1.33%

Older signals for HALO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Solid Tumors Antibodies Diabetes Mellitus Clinical Trial Product Hoffmann La Roche Halozyme Hyaluronidase
Is HALO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 18.76
52 Week Low 13.24
Average Volume 708,928
200-Day Moving Average 16.1553
50-Day Moving Average 16.4442
20-Day Moving Average 16.2115
10-Day Moving Average 16.315
Average True Range 0.4834
ADX 11.48
+DI 16.4203
-DI 17.1342
Chandelier Exit (Long, 3 ATRs ) 15.3998
Chandelier Exit (Short, 3 ATRs ) 16.8902
Upper Bollinger Band 16.7627
Lower Bollinger Band 15.6603
Percent B (%b) 0.57
BandWidth 6.800111
MACD Line 0.0014
MACD Signal Line -0.0394
MACD Histogram 0.0408
Fundamentals Value
Market Cap 2.18 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -17.52
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.91
Resistance 3 (R3) 16.96 16.82 16.80
Resistance 2 (R2) 16.82 16.66 16.79 16.77
Resistance 1 (R1) 16.55 16.56 16.48 16.50 16.73
Pivot Point 16.41 16.41 16.37 16.38 16.41
Support 1 (S1) 16.14 16.25 16.07 16.09 15.85
Support 2 (S2) 16.00 16.15 15.97 15.81
Support 3 (S3) 15.73 16.00 15.78
Support 4 (S4) 15.68